Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients
Haya Almalag,1 Hanan H Abouzaid,1 Lamya Alnaim,1 Jawza Albaqami,1 Rawan Al Shalhoub,1 Ibrahim Almaghlouth,2,3 Maha Dessougi,4 Amal Al Harthi,4 Mohamed Bedaiwi,2 Eman Alfi,5 Mohammed A Omair2 1Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 2Rheumatol...
Guardado en:
Autores principales: | Almalag H, Abouzaid HH, Alnaim L, Albaqami J, AlShalhoub R, Almaghlouth I, Dessougi M, Al Harthi A, Bedaiwi M, Alfi E, Omair MA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ed34b516146499496d5e3637dee9664 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment
por: Karel Hloch, et al.
Publicado: (2021) -
Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis
por: Zhao J, et al.
Publicado: (2017) -
Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration
por: Tingting Guo, et al.
Publicado: (2021) -
Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats
por: Liu YZ, et al.
Publicado: (2015) -
Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
por: Ivan Padjen, et al.
Publicado: (2020)